Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Facing A Liquidity Crunch; Dilution Ahead?
April 29, 2024
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
KNSA Stock News and Mentions of Kiniksa Pharmaceuticals, Ltd. Stocktwits
Updated: April 30, 2024 (09:26)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Kiniksa Pharmaceuticals Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Kiniksa Pharmaceuticals, Ltd. (KNSA).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Kiniksa Pharmaceuticals stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Kiniksa Pharmaceuticals, Ltd. (KNSA)
April 23, 2024 (12:40) / "Zacks Commentary" (by Zacks Equity Research)
Kiniksa Pharmaceuticals, Ltd. ( KNSA ) Reports Q1 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
April 23, 2024 (11:30) / "GlobeNewswire" (by Ltd.)
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
- ARCALYST® ( rilonacept ) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $370 - $390 million -- Abiprubart Phase 2b trial in Sjögren's Disease planned to initiate in 2H 2024 -- Current operating ...
In Article Trend: Neutral
April 8, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.
In Article Trend: Somewhat-Bullish
April 2, 2024 (11:30) / "GlobeNewswire" (by Kiniksa Pharmaceuticals)
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
- Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 -- Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity -- Abiprubart development in Sjogren's Disease fully funded through Phase 3 -- Company expects to remain cash flow ...
In Article Trend: Neutral
March 20, 2024 (13:36) / "Investor Ideas"
Doctor's Orders - biotech stocks to watch ( NASDAQ: LVTX ) ( NASDAQ: NKGN ) ( Nasdaq: KNSA ) ( Nasdaq: GOSS )
Doctor's Orders - biotech stocks to watch ( NASDAQ: LVTX ) ( NASDAQ: NKGN ) ( Nasdaq: KNSA ) ( Nasdaq: GOSS ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (18:23) / "Zacks Commentary" (by Zacks Equity Research)
Arcturus ( ARCT ) Stock Surges 73% in 3 Months: Here's Why
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
In Article Trend: Neutral
March 1, 2024 (14:55) / "Zacks Commentary" (by Zacks Equity Research)
Does Kiniksa Pharmaceuticals, Ltd. ( KNSA ) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (14:39) / "Zacks Commentary" (by Zacks Equity Research)
Puma Biotechnology ( PBYI ) Q4 Earnings & Revenues Lag Estimates
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
In Article Trend: Neutral
Related stocks from Healthcare sector
Allogene Therapeutics, Inc. (ALLO)
Esperion Therapeutics, Inc. (ESPR)
Mesoblast Limited (MESO)
IO Biotech, Inc. (IOBT)
EyePoint Pharmaceuticals, Inc. (EYPT)
Bristol-Myers Squibb Company (BMY)
Novartis AG (NVS)
Inspira Technologies Oxy B.H.N. Ltd. (IINN)
OKYO Pharma Limited (OKYO)
Trevi Therapeutics, Inc. (TRVI)
This website uses cookies to ensure you get the best experience on our website